OncoMatch/Clinical Trials/NCT07221253

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

Is NCT07221253 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Rilvegostomig and Durvalumab for biliary tract cancer.

Phase 3RecruitingAstraZenecaNCT07221253Data as of May 2026

Treatment: Rilvegostomig · Durvalumab · Gemcitabine/Cisplatin — The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cholangiocarcinoma

Biomarker criteria

Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: systemic therapy

Any prior systemic therapy received for unresectable, locally advanced or metastatic BTC.

Cannot have received: immune-regulatory receptor or mechanism targeting therapy

Any prior exposure to any other therapy targeting immune-regulatory receptors or mechanisms.

Lab requirements

Blood counts

adequate bone marrow function

Kidney function

adequate organ function

Liver function

adequate organ function

Adequate bone marrow and organ function.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Research Site · Birmingham, Alabama
Research Site · Phoenix, Arizona
Research Site · Tucson, Arizona
Research Site · Duarte, California
Research Site · Orange, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify